ReShape Lifesciences Inc. Common Stock
RSLS
RSLS was delisted on the 28th of December, 2018.
15 hedge funds and large institutions have $152K invested in ReShape Lifesciences Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
36% more funds holding
Funds holding: 11 → 15 (+4)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
81% less capital invested
Capital invested by funds: $818K → $152K (-$666K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.41M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$139K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$119K |
| 4 |
VF
Virtu Financial
New York
|
+$111K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$68.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$38K |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$9K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.43K |
| 4 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
-$4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1K |
RSLS Hedge Fund Activity: Q3 2018 in Review
15 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in ReShape Lifesciences Inc. Common Stock (RSLS) for Q3 2018, worth a combined $152K — down 81% from $818K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RSLS positions and 4 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.41M. The largest seller was CVI Holdings, exiting entirely with an estimated $38K sold.
- 15 institutional investors held ReShape Lifesciences Inc. Common Stock (RSLS) as of Q3 2018, up from 11 in Q2 2018.
- Funds reported $152K of ReShape Lifesciences Inc. Common Stock stock for Q3 2018, down 81% quarter-over-quarter.
- 8 funds opened new ReShape Lifesciences Inc. Common Stock positions in Q3 2018 and 4 closed out, a net change of +4 holders.
- The largest ReShape Lifesciences Inc. Common Stock buyer in Q3 2018 was Renaissance Technologies, an estimated $1.41M added.
- The largest ReShape Lifesciences Inc. Common Stock seller in Q3 2018 was CVI Holdings, an estimated $38K sold.
Based on aggregated 13F filings for Q3 2018.